The therapy met its primary endpoints in two Phase 3 studies and offers a new approach for the tens of millions of people living with the psychiatric condition.
Researchers identified schizophrenia risk genes that mediate placental, rather than brain, function, revealing new insight into the disease’s developmental origins.
Amit Etkin embraces the diverse underpinnings of depression and other psychiatric disorders and pairs patients with drugs based on their unique biology.